October isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…

Go here to discover the coin that could define this historic bull run with gains kicking off this mo

TCRX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.76%

Insider Buying (Last 12 Months): $248,928.70

Insider Selling (Last 12 Months): $951,885.08

TScan Therapeutics Insider Trading History Chart

TScan Therapeutics Share Price & Price History

^$5.51

▲ +0.23 (4.36%)

As of 10/4/2024 01:00 AM ET

Days: 30 | 90 | 365

Next opportunity for crypto millions

From Crypto 101 Media | Ad

"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive gains. This year could be off the charts. Don't let this opportunity pass you by. In crypto, timing is everything.

Go here to discover the #1 crypto set to dominate Uptober.

TScan Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/23/2024	Barbara Klencke	Director	Buy	5,000	$5.29	$26,450.00	45,000
8/26/2024	Barbara Klencke	Director	Buy	5,000	$5.53	$27,650.00	40,000
8/23/2024	Barbara Klencke	Director	Buy	5,000	$5.69	$28,450.00	35,000
8/23/2024	Zoran Zdraveski	Insider	Sell	164,686	$5.78	$951,885.08	4,716
12/18/2023	Timothy J Barberich	Director	Buy	28,830	$4.89	$140,978.70	66,710
12/14/2023	Barbara Klencke	Director	Buy	5,000	$5.08	$25,400.00	30,000
6/2/2023	Timothy J Barberich	Director	Buy	37,880	$2.63	$99,624.40	37,880
5/31/2023	Lynx1 Capital Management Lp	Major Shareholder	Sell	25,400	$2.52	$64,008.00	5,224,600
12/27/2022	Brian M. Silver	CFO	Buy	2,842	$1.50	$4,263.00	29,727
5/18/2022	David P Southwell	CEO	Buy	25,000	$3.59	$89,750.00	171,569
3/24/2022	Brian M. Silver	CFO	Buy	15,000	$3.40	$51,000.00

Who are Nvidia’s New Silent Partners?

From Weiss Ratings | Ad

Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.

I call these Nvidia’s “Silent Partners.”

SEC Filings (Institutional Ownership Changes) for TScan Therapeutics (NASDAQ:TCRX)

82.83% of TScan Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

TScan Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
10/3/2024	SG Americas Securities LLC	15,563	$78K	0.0%	N/A	0.029%
8/15/2024	The Manufacturers Life Insurance Company	15,383	$90K	0.0%	N/A	0.029%
8/15/2024	Troluce Capital Advisors LLC	92,832	$0.54M	0.1%	N/A	0.176%
8/14/2024	Great Point Partners LLC	940,831	$5.50M	1.1%	N/A	1.780%
8/14/2024	Marshall Wace LLP	307,487	$1.80M	0.0%	+60.8%	0.582%
8/14/2024	Bank of Montreal Can	120,454	$0.75M	0.0%	N/A	0.228%
8/12/2024	Marathon Trading Investment Management LLC	13,600	$80K	0.0%	-73.3%	0.026%
8/9/2024	Renaissance Technologies LLC	80,000	$0.47M	0.0%	+70.2%	0.151%
8/9/2024	Dimensional Fund Advisors LP	11,882	$70K	0.0%	N/A	0.022%
8/9/2024	Brown Brothers Harriman & Co.	76,024	$0.45M	0.0%	N/A	0.144%
8/8/2024	Cornercap Investment Counsel Inc.	22,940	$0.13M	0.0%	N/A	0.043%
8/8/2024	American Century Companies Inc.	47,481	$0.28M	0.0%	+48.9%	0.090%
8/2/2024	Privium Fund Management UK Ltd	12,103	$69K	0.0%	-23.5%	0.023%
8/1/2024	Rhumbline Advisers	46,867	$0.27M	0.0%	N/A	0.089%
7/26/2024	Bank of New York Mellon Corp	116,658	$0.68M	0.0%	N/A	0.221%
5/10/2024	Vanguard Group Inc.	1,808,152	$14.36M	0.0%	+1.1%	3.776%
5/10/2024	Tocqueville Asset Management L.P.	212,200	$1.69M	0.0%	N/A	0.443%
4/17/2024	Cannon Global Investment Management LLC	17,500	$0.14M	0.4%	N/A	0.037%
2/14/2024	Pale Fire Capital SE	21,573	$0.13M	0.0%	+30.2%	0.045%
2/12/2024	Letko Brosseau & Associates Inc.	20,700	$0.12M	0.0%	-36.1%	0.043%
1/31/2024	abrdn plc	200,000	$1.17M	0.0%	N/A	0.418%
11/14/2023	Pale Fire Capital SE	16,575	$42K	0.0%	N/A	0.035%
11/9/2023	Letko Brosseau & Associates Inc.	32,400	$83K	0.0%	N/A	0.068%
8/15/2023	BVF Inc. IL	2,989,474	$7.47M	0.2%	N/A	12.338%
8/10/2023	Monashee Investment Management LLC	400,000	$1M	0.2%	N/A	1.651%
7/26/2023	Privium Fund Management B.V.	15,825	$40K	0.0%	N/A	0.065%
5/10/2023	Simplify Asset Management Inc.	546,916	$1.15M	0.2%	N/A	2.257%
2/15/2023	Tang Capital Management LLC	514,655	$0.80M	0.1%	-7.8%	2.137%
11/16/2022	Alphabet Inc.	1,077,080	$3.29M	0.2%	N/A	4.482%
11/15/2022	Tang Capital Management LLC	557,915	$1.70M	0.2%	-25.4%	2.322%
11/4/2022	Prudential Financial Inc.	11,000	$34K	0.0%	N/A	0.046%
11/1/2022	Privium Fund Management UK Ltd	15,825	$48K	0.1%	N/A	0.066%
5/17/2022	RA Capital Management L.P.	1,021,764	$2.86M	0.1%	-18.6%	4.299%
5/17/2022	Hhlr Advisors LTD.	669,513	$1.88M	0.0%	-47.8%	2.817%
4/26/2022	Marquette Asset Management LLC	28,895	$81K	0.0%	+33.7%	0.122%
2/15/2022	Deer Management Co. LLC	1,245,505	$5.61M	0.1%	N/A	5.240%
2/15/2022	Adage Capital Partners GP L.L.C.	550,000	$2.48M	0.0%	+10.8%	2.314%
1/19/2022	Marquette Asset Management LLC	21,618	$97K	0.0%	N/A	0.091%
11/16/2021	Schonfeld Strategic Advisors LLC	22,200	$0.19M	0.0%	N/A	0.093%
11/16/2021	Wellington Management Group LLP	139,566	$1.16M	0.0%	N/A	0.582%
11/15/2021	RA Capital Management L.P.	1,255,317	$10.47M	0.1%	N/A	5.238%
11/15/2021	Caas Capital Management LP	75,000	$0.63M	0.0%	N/A	0.313%
11/12/2021	DC Investments Management LLC	35,563	$0.30M	0.6%	N/A	0.148%
11/12/2021	DC Funds LP	630,000	$5.25M	20.6%	N/A	2.629%
11/9/2021	BlackRock Inc.	1,500,577	$12.52M	0.0%	N/A	6.261%
11/9/2021	Monashee Investment Management LLC	100,000	$0.83M	0.2%	N/A	0.417%

Data available starting January 2016

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $5.51

$5.26

$5.55

50 Day Range

MA: $5.77

$4.97

$7.27

52 Week Range

Now: $5.51

$2.55

$9.69

Volume

287,661 shs

Average Volume

223,766 shs

Market Capitalization

$291.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Who are the company insiders with the largest holdings of TScan Therapeutics?: TScan Therapeutics' top insider shareholders include:
Lynx1 Capital Management Lp (Major Shareholder)
Timothy J Barberich (Director)
Barbara Klencke (Director)
Brian M Silver (CFO)
Zoran Zdraveski (Insider)
Learn More about top insider investors at TScan Therapeutics.
Who are the major institutional investors of TScan Therapeutics?: TScan Therapeutics' top institutional investors include:
SG Americas Securities LLC — 0.03%
Learn More about top institutional investors of TScan Therapeutics stock.
Which major investors are buying TScan Therapeutics stock?: Within the previous quarter, TCRX stock was acquired by institutional investors including:
SG Americas Securities LLC
In the previous year, these company insiders have bought TScan Therapeutics stock:
Lynx1 Capital Management Lp (Major Shareholder)
Timothy J Barberich (Director)
Barbara Klencke (Director)
Learn More investors buying TScan Therapeutics stock.